Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by recurrent flares and remissions, with intense and persistent pruritus and variable clinical presentation. The primary therapeutic objectives are to reduce skin lesions, minimize flare-ups, and decrease overall disease burden. Topical corticosteroids and topical calcineurin inhibitors remain central to topical management in pediatric AD. However, due to long-term side effects, continuous use is not recommended. Hence, recent advancements have shifted toward novel and targeted topical therapies, which show potential in improving disease outcomes in mild-to-moderate AD. Nevertheless, long-term, large-scale studies are essential to fully assess their safety and efficacy. This consensus document aims to update the general management and upcoming therapies in pediatric AD.
Dixit et al. (Wed,) studied this question.